BCM
SRNE

Birch Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Birch Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5
Closed – – 111
2020
Q2 		$0 Buy
+5
New +$19 ﹤0.01% 104

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Birch Capital Management's SRNE Position: Q3 2020 in Review

Birch Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 5 shares.

Birch Capital Management first reported a position in SRNE in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Birch Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Birch Capital Management sold 5 Sorrento Therapeutics, Inc. shares in Q3 2020.
  • Birch Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Birch Capital Management's Sorrento Therapeutics, Inc. position peaked at $0 in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Birch Capital Management's 13F filing for Q3 2020, filed 6 Oct 2020.